Unknown

Dataset Information

0

Common helical V1V2 conformations of HIV-1 Envelope expose the ?4?7 binding site on intact virions.


ABSTRACT: The ?4?7 integrin is a non-essential HIV-1 adhesion receptor, bound by the gp120 V1V2 domain, facilitating rapid viral dissemination into gut-associated lymphoid tissues. Antibodies blocking this interaction early in infection can improve disease outcome, and V1V2-targeted antibodies were correlated with moderate efficacy reported from the RV144 HIV-1 vaccine trial. Monoclonal ?4?7-blocking antibodies recognise two slightly different helical V2 conformations, and current structural data suggests their binding sites are occluded in prefusion envelope trimers. Here, we report cocrystal structures of two ?4?7-blocking antibodies from an infected donor complexed with scaffolded V1V2 or V2 peptides. Both antibodies recognised the same helix-coil V2 conformation as RV144 antibody CH58, identifying a frequently sampled alternative conformation of full-length V1V2. In the context of Envelope, this ?-helical form of V1V2 displays highly exposed ?4?7-binding sites, potentially providing a functional role for non-native Envelope on virion or infected cell surfaces in HIV-1 dissemination, pathogenesis, and vaccine design.

SUBMITTER: Wibmer CK 

PROVIDER: S-EPMC6203816 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions.

Wibmer Constantinos Kurt CK   Richardson Simone I SI   Yolitz Jason J   Cicala Claudia C   Arthos James J   Moore Penny L PL   Morris Lynn L  

Nature communications 20181026 1


The α4β7 integrin is a non-essential HIV-1 adhesion receptor, bound by the gp120 V1V2 domain, facilitating rapid viral dissemination into gut-associated lymphoid tissues. Antibodies blocking this interaction early in infection can improve disease outcome, and V1V2-targeted antibodies were correlated with moderate efficacy reported from the RV144 HIV-1 vaccine trial. Monoclonal α4β7-blocking antibodies recognise two slightly different helical V2 conformations, and current structural data suggests  ...[more]

Similar Datasets

| S-EPMC5430429 | biostudies-literature
| S-EPMC10865856 | biostudies-literature
| S-EPMC3818118 | biostudies-literature
| S-EPMC3510489 | biostudies-literature
| S-EPMC10465357 | biostudies-literature
| S-EPMC5078604 | biostudies-literature
| S-EPMC4619609 | biostudies-literature
| S-EPMC5472438 | biostudies-literature
| S-EPMC9762554 | biostudies-literature
| S-EPMC2922250 | biostudies-literature